Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Lisata Therapeutics, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
LSTA
Nasdaq
2830
www.lisata.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Lisata Therapeutics, Inc.
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference
- Feb 5th, 2025 1:30 pm
Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
- Jan 23rd, 2025 1:00 pm
Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
- Jan 22nd, 2025 1:00 pm
Lisata Therapeutics to Present at the 2025 Sequire Investor Summit
- Jan 15th, 2025 1:30 pm
US Penny Stocks To Watch In January 2025
- Jan 9th, 2025 5:10 pm
Lisata completes subject enrolment in multi-cancer trial of certepetide
- Dec 11th, 2024 3:52 pm
Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial
- Dec 11th, 2024 3:28 pm
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
- Dec 10th, 2024 1:30 pm
Lisata and Kuva Labs partner for MR imaging agents to detect cancer
- Dec 4th, 2024 11:28 am
Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging
- Dec 3rd, 2024 1:30 pm
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
- Nov 19th, 2024 1:30 pm
Q3 2024 Lisata Therapeutics Inc Earnings Call
- Nov 13th, 2024 1:44 pm
Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ...
- Nov 13th, 2024 7:16 am
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- Nov 12th, 2024 9:05 pm
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
- Nov 6th, 2024 2:23 pm
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
- Nov 6th, 2024 1:30 pm
Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know
- Nov 1st, 2024 4:00 pm
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
- Oct 31st, 2024 12:30 pm
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
- Oct 28th, 2024 12:30 pm
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
- Oct 3rd, 2024 12:00 pm
Scroll